Ergoteles LLC Agios Pharmaceuticals, Inc. Transaction History

Ergoteles LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$21.38 - $29.19 $591,028 - $806,928	27,644 Added 108.47%	53,129 $1.5 Million
Q1 2023 May 10, 2023	BUY	$21.74 - $30.93 $554,043 - $788,251	25,485 New	25,485 $585,000
Q2 2022 Aug 12, 2022	BUY	$17.06 - $31.42 $92,823 - $170,956	5,441 Added 45.0%	17,533 $389,000
Q1 2022 May 13, 2022	SELL	$26.68 - $34.81 $1.43 Million - $1.87 Million	-53,732 Reduced 81.63%	12,092 $352,000
Q4 2021 Feb 14, 2022	BUY	$29.58 - $49.78 $1.95 Million - $3.28 Million	65,824 New	65,824 $2.16 Million
Q2 2021 Aug 12, 2021	SELL	$52.06 - $61.27 $3.98 Million - $4.68 Million	-76,419 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$44.23 - $57.5 $1.54 Million - $2.01 Million	34,907 Added 84.09%	76,419 $3.95 Million
Q4 2020 Feb 11, 2021	BUY	$33.21 - $46.54 $283,779 - $397,684	8,545 Added 25.92%	41,512 $1.8 Million
Q3 2020 Nov 16, 2020	BUY	$33.87 - $55.93 $1.12 Million - $1.84 Million	32,967 New	32,967 $1.15 Million

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.89B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.